Fenofibrate and risk of end-stage renal disease: A nationwide cohort study.
Young Youl HyunKyung-Soo KimSangmo HongKyungdo HanCheol Young ParkPublished in: Diabetes, obesity & metabolism (2024)
Fenofibrate use in patients taking statins with either hypertension, proteinuria, or decreased estimated glomerular filtration rate is associated with a low risk of incident end-stage renal disease. To confirm the renoprotective effect of fenofibrate in chronic kidney disease, a randomized controlled trial is warranted.